Exhibit 10.6


 


CYANOGEN INC.


 


SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT


 


December 24, 2014


 






     


     


    

 


TABLE OF CONTENTS


 


	 	 	 	 	Page
	 	 	 	 	 
	1.	Definitions	 	1
	2.	Registration Rights	 	5
	 	2.1	Demand Registration	 	6
	 	2.2	Company Registration	 	6
	 	2.3	Underwriting Requirements	 	6
	 	2.4	Obligations of the Company	 	7
	 	2.5	Furnish Information	 	9
	 	2.6	Expenses of Registration	 	9
	 	2.7	Delay of Registration	 	9
	 	2.8	Indemnification	 	9
	 	2.9	Reports Under Exchange Act	 	11
	 	2.10	Limitations on Subsequent Registration Rights	 	11
	 	2.11	“Market Stand-off” Agreement	 	12
	 	2.12	Restrictions on Transfer	 	12
	 	2.13	Termination of Registration Rights	 	13
	3.	Information and Observer Rights	 	13
	 	3.1	Delivery of Financial Statements	 	13
	 	3.2	Inspection	 	15
	 	3.3	Observer Rights	 	15
	 	3.4	Termination of Information and Observer Rights	 	15
	 	3.5	Confidentiality	 	16
	4.	Rights to Future Stock Issuances	 	16
	 	4.1	Right of First Offer	 	16
	 	4.2	Termination	 	18
	5.	Additional Covenants	 	18
	 	5.1	Employee Agreements	 	18
	 	5.2	Employee Stock	 	18
	 	5.3	Qualified Small Business Stock	 	18
	 	5.4	Successor Indemnification	 	19
	 	5.5	Termination of Covenants	 	19
	6.	Miscellaneous	 	19
	 	6.1	Successors and Assigns	 	19
	 	6.2	Governing Law	 	20
	 	6.3	Counterparts	 	20
	 	6.4	Titles and Subtitles	 	20
	 	6.5	Notices	 	20
	 	6.6	Amendments and Waivers	 	20
	 	6.7	Severability	 	21
	 	6.8	Aggregation of Stock	 	21
	 	6.9	Additional Investors	 	21
	 	6.10	Entire Agreement	 	21
	 	6.11	Dispute Resolution	 	21
	 	6.12	Fees and Expenses	 	22
	 	6.13	Delays or Omissions	 	22
	 	6.14	Acknowledgement	 	22



 


	Schedule A	-	Series A Investors
	Schedule B	-	Series B Investors
	Schedule C	-	Series C Investors
	Schedule D	-	Schedule of Key Holders



 



     


     


    

 


SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT


 


THIS SECOND AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 24th day of December 2014, by and among Cyanogen Inc., a Delaware corporation
(the “Company”), each of the holders of Shares of the Company’s Series A Preferred Stock, par value $0.00001
per share (the “Series A Preferred Stock”) listed on Schedule A hereto (the “Series A Investors”),
each of the holders of Shares of the Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series B Preferred
Stock”) listed on Schedule B hereto (the “Series B Investors”), each of the holders of Shares of the
Company’s Series C Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock,” and together
with the Series A Preferred Stock and Series B Preferred Stock, the “Preferred Stock”) listed on Schedule C
hereto (the “Series C Investors,” and together with the Series A Investors and the Series B Investors, the “Investors”)
and each of the stockholders listed on Schedule D hereto, each of whom is referred to herein as a “Key Holder”
and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section
6.9 hereof.


 


RECITALS


 


WHEREAS, the Company,
the Key Holders, the Series A Investors and the Series B Investors are party to that certain Amended and Restated Investors’ Rights
Agreement dated as of November 22, 2013 (the “Prior Rights Agreement”) and desire to amend and restate the Prior Voting
Agreement in accordance with Section 6.6 thereof;


 


WHEREAS, the Company
and the Series C Investors are parties to the Series C Preferred Stock Purchase Agreement of even date herewith (the “Purchase
Agreement”), pursuant to which the Series C Investors have agreed to purchase shares of Series C Preferred Stock; and


 


WHEREAS, the obligations
of the Company and the Series C Investors under the Purchase Agreement are conditioned on, among other things, the execution and delivery
of this Agreement by the parties hereto.


 


WHEREAS, the Company,
the Series A Investors, the Key Holders, and the Series C Investors desire to enter into this Agreement in order to amend, restate, and
replace the agreements and understandings of the parties under the Prior Rights Agreement with the agreements and understandings set forth
in this Agreement.


 


NOW, THEREFORE, the Company,
the Key Holders and the Investors agree as follows:


 


1.
Definitions. For purposes of this Agreement:


 


1.1 “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any
venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the
same management company with, such Person.


 






    1


     


    

 


1.2
“Common Stock” means shares of the Company’s common stock, par value $0.00001 per share.


 


1.3 “Competitor”
means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture
or similar arrangement (whether now existing or formed hereafter)), in the Company’s line of business, but shall not include any
financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 10% of the outstanding
equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the Board of Directors of
any Competitor.


 


1.4
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability
(or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to
be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any
rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.


 


1.5 “Derivative
Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly),
Common Stock, including options and warrants.


 


1.6 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


1.7
“Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company
or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction;
(iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered.


 


1.8 “FOIA
Party” means a Person that, in the determination of the Board of Directors, may be subject to, and thereby required to disclose
non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”),
any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar
statutory or regulatory requirement.


 






    2


     


    

 


1.9
“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form
under the Securities Act subsequently adopted by the SEC.


 


1.10 “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities
Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the
Company with the SEC.


 


1.11 “Holder”
means any holder of Registrable Securities who is a party to this Agreement.


 


1.12
“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a
natural person referred to herein.


 


1.13 “Initiating
Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.


 


1.14 “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act.


 


1.15
“Key Employee” means any executive-level employee of the Company.


 


1.16 “Key
Holder Registrable Securities” means (i) the 12,000,000 shares of Common Stock held by the Key Holders, and (ii) any Common
Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement of such shares.


 


1.17 “Major
Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least 1,000,000
shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof).


 


1.18 “New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options,
or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.


 


1.19 “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.


 


1.20 “Preferred
Director Approval” means the approval of each of the Series A Director or the Series B Director (as such terms are defined in
the Restated Certificate).


 






    3


     


    

 


1.21
“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities
of the Company, acquired by the Investors after the date hereof; (iii) the Key Holder Registrable Securities, provided,
however, that such Key Holder Registrable Securities shall not be deemed Registrable Securities and the Key Holders shall not be
deemed Holders for the purposes of Subsections 2.1, 2.10 and 6.6, and (iv) any Common Stock issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities
sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and
excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.


 


1.22 “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock
that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable
and/or convertible securities that are Registrable Securities.


 


1.23 “Restricted
Securities” means the securities of the Company required to bear the legend set forth in Subsection 2.12(b) hereof.


 


1.24 “SEC”
means the Securities and Exchange Commission.


 


1.25 “SEC
Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.


 


1.26 “SEC
Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.


 


1.27 “Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


1.28 “Selling
Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in Subsection 2.6.


 


1.29 “Special
Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least the number
of shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof) equivalent to, based on the price at which each such share was originally purchased by the Investor, an
aggregate investment of $15,000,000.


 






    4


     


    

 


2.
Registration Rights. The Company covenants and agrees as follows:


 


2.1
Demand Registration.


 


(a) Form
S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180)
days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least a majority
of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least forty
percent (40%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of
Selling Expenses, would exceed $15 million), then the Company shall (x) within ten (10) days after the date such request is given, give
notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable,
and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder
to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection
2.1(c) and Subsection 2.3.


 


(b) Form
S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders
of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement
with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses,
of at least $10 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to
all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection
2.1(c) and Subsection 2.3.


 


(c) Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate
signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors
it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain
effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking
action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however,
that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company
shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period
other than an Excluded Registration.


 






    5


     


    

 


(d) The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) (i) during
the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company
has effected one registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of
Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i)
during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date
that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company
is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)
if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding
the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d)
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw
their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration
statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected”
for purposes of this Subsection 2.1(d).


 


2.2 Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders
other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.
Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to
the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested
to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable
Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with Subsection 2.6.


 


2.3
Underwriting Requirements.


 


(a) If,
pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the
Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably
acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion
of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting
agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection
2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the
number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise
would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated
among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number
of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders;
provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall
not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest
one hundred (100) shares.


 






    6


     


    

 


(b) In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2,
the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders
accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters
in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold
(other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering,
then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which
the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters
determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to)
the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round
the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall
(i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be
sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the offering
be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in
which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s
securities are included in such offering or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable
Securities be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. For
purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder,
or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the
benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with
respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included
in such “selling Holder,” as defined in this sentence.


 


2.4 Obligations
of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:


 


(a) prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one
hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter
of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case
of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to
compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to 180 days, if necessary, to
keep the registration statement effective until all such Registrable Securities are sold;


 






    7


     


    

 


(b) prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;


 


(c) furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;


 


(d) use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;


 


(e) in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s) of such offering;


 


(f) use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;


 


(g) provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;


 


(h) promptly
make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration
statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees,
and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence in connection therewith;


 


(i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and


 






    8


     


    

 


(j) after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.


 


In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program
under Rule 10b5-1 of the Exchange Act.


 


2.5 Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2
with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to
effect the registration of such Holder’s Registrable Securities.


 


2.6 Expenses
of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and
disbursements of counsel for the Company; and the reasonable fees and disbursements not to exceed $25,000, of one counsel for the selling
Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the
Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration
request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which
case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in
the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration
pursuant to Subsection 2.1(a) or Subsection 2.1(b), as the case may be; provided further that if, at the time of
such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from
that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such
information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant
to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to
this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered
on their behalf.


 


2.7 Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2.


 


2.8 Indemnification.If
any Registrable Securities are included in a registration statement under this Section 2:


 


(a) To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or
the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration.


 






    9


     


    

 


(b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any
other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against
any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon
and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which
consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder
by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such
Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.


 


(c) Promptly
after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof.
The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory
to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices
the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8.


 


(d) To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise
entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection
2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party
hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any
other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission
of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable
Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection
2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from
the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct
or fraud by such Holder.


 






    10


     


    

 


(e) Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into
in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.


 


(f) Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration
under this Section 2, and otherwise shall survive the termination of this Agreement.


 


2.8 Reports
Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of
the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration
on Form S-3, the Company shall:


 


(a) make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO;


 


(b) use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and


 


(c) furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement
by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective
date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the
Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the
Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company
so qualifies to use such form).


 


2.9 Limitations
on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder
of any securities of the Company that would provide to such holder the right to include securities in any registration on other than a
subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities
that they wish to so include or allow such holder or prospective holder to initiate a demand for registration of any securities held by
such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party
to this Agreement in accordance with Subsection 6.9.


 






    11


     


    

 


2.10 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares
of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case
of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the
publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend;
offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option,
right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of
the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common
Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall only apply to the IPO,
shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders
only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain
a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration
are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power, and authority to enforce the provisions
hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the
underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further
effect thereto.


 


2.11
Restrictions on Transfer.


 


(a) The
Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize
and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder
to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.


 


(b) Each certificate or
instrument representing (i) the Preferred Stock, (i) the Registrable Securities, and (iii) any other securities issued in respect of
the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be stamped or otherwise imprinted
with a legend substantially in the following form:


 


THE SECURITIES REPRESENTED HEREBY HAVE
BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED
IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.


 


THE SECURITIES REPRESENTED HEREBY MAY
BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH
THE SECRETARY OF THE COMPANY.


 


The Holders consent
to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to
implement the restrictions on transfer set forth in this Subsection 2.12.


 






    12


     


    

 


(c) The
holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s
intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale,
pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense
by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company,
addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)
a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities
without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted
Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be
entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the
Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with
SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration;
provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate or
instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to
SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate shall not bear such
restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance
with any provisions of the Securities Act.


 


2.12 Termination
of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Subsection 2.1 or Subsection 2.2 shall terminate upon the earliest to occur of:


 


(a) the
closing of a Deemed Liquidation Event, as such term is defined in the Company’s Third Amended and Restated Certificate of Incorporation
(the “Restated Certificate”), in which the consideration received by the Investors is in the form of cash and/or marketable
securities;


 


(b) such
time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; and


 


(c) the
fifth anniversary of the Qualified Public Offering (as defined in the Restated Certificate).


 


3.
Information and Observer Rights.


 


3.1 Delivery
of Financial Statements. The Company shall deliver to each Special Investor, provided that the Board of Directors has not reasonably
determined that such Special Investor is a competitor of the Company (provided that no Special Investor that is a venture capital
firm shall be deemed a competitor solely as a result of its investment in other companies):


 


(a) as soon as practicable, but in any event
within one-hundred twenty (120) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such
year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end
of such year, all such financial statements to be prepared in accordance with generally accepted accounting principles
(“GAAP”) (provided that the Board of Directors (including the Preferred Director Approval) may waive the
requirement that such financial statements be prepared in accordance with GAAP) and audited and certified by independent public
accountants of nationally recognized standing selected by the Company, provided that no such audit shall be required for
fiscal year 2014;


 






    13


     


    

 


(b) as
soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal
year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement
of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year- end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with
GAAP), provided that the Board of Directors (including the Preferred Director Approval) may waive the requirement that such financial
statements be prepared in accordance with GAAP;


 


(c) Upon
request of a Special Investor as soon as practicable, but in any event within thirty (30) days after the end of each month, an unaudited
income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared
in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain
all notes thereto that may be required in accordance with GAAP), provided that the Board of Directors (including the Preferred
Director Approval) may waive the requirement that such financial statements be prepared in accordance with GAAP;


 


(d) as
soon as practicable, but in any event forty-five (45) days before the end of each fiscal year, a budget and business plan for the next
fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and,
promptly after prepared, any other budgets or revised budgets prepared by the Company; and


 


(e) such
other information relating to the financial condition of the Company as any Special Investor may from time to time reasonably request;
provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that
the Company reasonably determines in good faith to be a trade secret or confidential information, or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel.


 


If, for any period,
the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company
and all such consolidated subsidiaries.


 


Notwithstanding anything
else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1
during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related
offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.


 






    14


     


    

 


3.2 Inspection.
The Company shall permit each Special Investor (provided that the Board of Directors has not reasonably determined that such Special
Investor is a competitor of the Company (provided that no Special Investor that is a venture capital firm shall be deemed a competitor
solely as a result of its investment in other companies)), at such Special Investor’s expense, to visit and inspect the Company’s
properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers,
during normal business hours of the Company as may be reasonably requested by the Special Investor; provided, however, that
the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and
in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement,
in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company
and its counsel.


 


3.3 Observer
Rights. As long as PI International Holdings LLC (“PI”) owns not less than twenty-five percent percent (25%) of
the shares of the Series C Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued
upon conversion thereof), the Company shall invite a representative of PI, who shall initially be Sandesh Patnam, to attend all meetings
of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner
with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information
and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict
of interest, or if such Investor or its representative is a competitor of the Company (provided that PI shall not be deemed a competitor,
or to have a conflict of interest, solely as a result of its investment in other companies, except for any such company that could be
reasonably be viewed as a direct competitor of the Company). In the event Mr. Patnam shall cease to serve as the designated representative
of PI to attend all meetings of the Board of Directors in a nonvoting observer capacity, subject to the reasonable approval of the Board
of Directors, PI may designate another representative to serve in such capacity.


 


3.4 Termination
of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3
shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified Public Offering, as such term
is defined in the Restated Certificate, (ii) when the Company first becomes subject to the periodic reporting requirements of Section
12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, in
which the consideration received by the Investors is in the form of cash and/or marketable securities, whichever event occurs first.


 






    15


     


    

 


3.5 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor
its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes
known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been
independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been
made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have
to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment
in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees
to be bound by the provisions of this Subsection 3.5; provided that (x) the Investor provides such prospective purchaser's
identity to the Company prior to any disclosure of confidential information and (y) the Board of Directors confirms in writing that it
has not reasonably determined that such prospective purchaser is a competitor of the Company; (iii) to any existing Affiliate, partner,
member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information;
or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes
reasonable steps to minimize the extent of any such required disclosure.


 


4.
Rights to Future Stock Issuances.


 


4.1 Right
of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes
to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall
be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself,
(ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial
ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (“Investor
Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner: (x) is not a Competitor or FOIA
Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter
into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the
Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided
that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1, 3.2
and 4.1 hereof).


 






    16


     


    

 


(a) The
Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes
to offer such New Securities.


 


(b) By
notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion
that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor)
bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred
Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major
Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of
any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice,
each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed
for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly)
upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed
shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date
that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).


 


(c) If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1, offer and
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more
favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the
New Securities within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right
provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors
in accordance with this Subsection 4.1.


 






    17


     


    

 


(d) The
right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate);
(ii) shares of Common Stock issued in the IPO; (iii) the issuance of shares of Series C Preferred Stock to Additional Purchasers pursuant
to Subsection 1.3 of the Purchase Agreement; and (iv) the issuance of securities that, with unanimous approval of the Company’s
Board of Directors, are not offered to any existing stockholder of the Company.


 


4.2 Termination.
The covenants set forth in Subsection 4 shall terminate and be of no further force or effect (i) immediately before the consummation
of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange
Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, in which the consideration received
by the Investors is in the form of cash and/or marketable securities, whichever event occurs first.


 


5.
Additional Covenants.


 


5.1 Employee
Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or
any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement, substantially
in the form approved by the Board of Directors.


 


5.2 Employee
Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive
options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first
twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar
to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right
of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at
cost upon termination of employment of a holder of restricted stock, and there shall be no provision for acceleration of vesting.


 


5.3 Qualified
Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Series C Preferred Stock issued
pursuant to the Purchase Agreement, as well as any shares into which such shares are converted, within the meaning of Section 1202(f)
of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors
of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the
Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may
be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business
days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written
statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business
stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s
possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest
in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code.


 






    18


     


    

 


5.4 Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not
the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members
of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be.


 


5.5 Termination
of Covenants. The covenants set forth in this Section 5, except for Subsection 5.4, shall terminate and be of no further
force or effect (i) immediately before the consummation of the IPO (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation, whichever event occurs first.


 


6.
Miscellaneous.


 


6.1 Successors
and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of
Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit
of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 500,000
shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations);
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice
of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and
(y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of
this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable
Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s
Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member
shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices,
or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the
respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided herein.


 






    19


     


    

 


6.2 Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware.


 


6.3 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.


 


6.4 Titles
and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.


 


6.5 Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or
facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s
next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying
next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses
as set forth on Schedules A, B, C or D (as applicable) hereto, or to the principal office of the Company and
to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy
shall also be sent to Buddy Arnheim, 3150 Porter Drive, Palo Alto, CA 94304-1212 and if notice is given to Stockholders, a copy shall
also be given to Pillsbury Winthrop Shaw Pittman LLP, 2550 Hanover Street, Palo Alto, CA 94304, Attn: Armando Castro.


 


6.6 Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of
a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance
with Subsection 2.12(c); and provided further that any provision hereof may be waived by any waiving party on such party’s
own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and
the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver
does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities
in such transaction). Further, this Agreement may not be amended, and no provision hereof may be waived, in each case, in any way which
would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver
would have on the rights of the Investors hereunder, without also the written consent of the holders of at least a majority of the Registrable
Securities held by the Key Holders. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to
any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected
in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented
thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed
to be or construed as a further or continuing waiver of any such term, condition, or provision.


 






    20


     


    

 


6.7 Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.


 


6.8 Aggregation
of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner
they deem appropriate.


 


6.9 Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s
Series C Preferred Stock after the date hereof, any purchaser of such shares of Series C Preferred Stock may become a party to this Agreement
by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor”
for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor”
hereunder.


 


6.10 Entire
Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement
among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled.


 


6.11 Dispute
Resolution. Any unresolved controversy or claim arising out of or relating to this Agreement, except as (i) otherwise provided in
this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which a
provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties,
and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration
Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the
type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in the State of California, County
of San Mateo, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding
and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows:
(a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated,
(b) depositions of all party witnesses and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause.
Depositions shall be conducted in accordance with the laws of the State of Delaware, the arbitrator shall be required to provide in writing
to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting
the official transcript of such proceedings. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary
disbursements in addition to any other relief to which such party may be entitled.


 






    21


     


    

 


6.12 Fees
and Expenses. Subject to Section 6.11, if any action at law or in equity is necessary to enforce or interpret the terms of
the Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition
to any other relief to which such party may be entitled.


 


6.13 Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.


 


6.14 Acknowledgement.
The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and
related proprietary information of many enterprises, including enterprises which may have products or services which compete directly
or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing
or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the
Company.


 


[Signature Pages Follow]


 




    22


     


    

 


IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.


 


	 	CYANOGEN INC.
	 	 
	 	By: 	/s/ Kirt McMaster
	 	 	Kirt McMaster-
	 	 	Chief Executive
	 	 
	 	Officer’s Address:
	 	516 High Street
	 	Palo Alto, CA 94301


 


SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above.


 


	 	Steven Kondik
	 	 
	 	By:	/s/ Steven Kondik
	 	 
	 	Address:  20182 110th Pl SE
	 	               Kent, WA 98031
	 	 
	 	Kirt McMaster
	 	 
	 	By:	 /s/ Kirt McMaster
	 	Address:  3003 Olin Avenue, #1 l 7
	 	               San Jose, CA 95128
	 	 
	 	Tom Moss
	 	 
	 	By: 	/s/ Tom Moss           
	 	Address:  94 Pepper Drive
	 	               Los Altos, CA 94022
	 	 
	 	Koushik Dutta
	 	 
	 	By: 	/s/ Koushik Dutta
	 	Address:  2929 1st Avenue 600
	 	               Seattle, WA 98121


  


SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date written above. 


 


	 	PURCHASER:
	 	 
	 	PI INTERNATIONAL HOLDINGS LLC
	 	 
	 	By: 	/s/ Rejesh Ramaiah         
	 	Name: 	 Rajesh Ramaiah
	 	Title: 	Authorized Signatory
	 	 
	 	Address:
	 	 
	 	455 N. Whisman Road, Suite 100
	 	Mountain View, CA 94043


 


SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date written above.


 


	 	ANDREESSEN HOROWITZ FUND III, L.P.
	 	for itself and as nominee for Andreessen Horowitz Fund III-A, L.P.,
	 	Andreessen Horowitz Fund III-B, L.P. and Andreessen Horowitz Fund III-Q, L.P.
	 	 	 
	 	By: 	AH Equity Partners III, L.L.C. 
	 	 	Its general partner
	 	 	 
	 	By:	/s/ Ben Horowitz
	 	Name: 	Ben Horowitz
	 	Title: 	Managing Member         
	 	 	 
	 	Address:
	 	 	 
	 	2865 Sand Hill Road Suite 101
	 	Menlo Park, CA 94025


 


SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date written above. 


 


	 	BENCHMARK CAPITAL PARTNERS VI, L.P.
	 	as nominee for
	 	Benchmark Capital Partners VI, L.P.,

                                                Benchmark Founders' Fund VI, L.P.,

                                                Benchmark Founders' Fund VI-B, L.P.

 and related individuals

	 	 	 
	 	By:	Benchmark Capital Management Co. VI,
	 	 	L.L.C., its general partner
	 	 	 
	 	By:	/s/ Mitch Lasky
	 		Managing Member
	 	 	 
		Address: 
	 	 	 
	 	2965 Woodside Road
	 	Woodside, CA 94062
	 	 	 
		BENCHMARK CAPITAL PARTNERS VII, L.P.
	 	as nominee for
	 	Benchmark Capital Partners VII, L.P.,

                                                Benchmark Founders' Fund VII, L.P.,

                                                Benchmark Founders' Fund VII-B, L.P.

	 	 	 
	 	By:	Benchmark Capital Management Co. VI, 
	 		L.L.C., its general partner
	 	 	 
	 	By:	/s/ Mitch Lasky
	 		Managing Member
	 	 	 
	 	Address:
	 	 	 
	 	2965 Woodside Road
	 	Woodside, CA 94062


 


SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC. 


 




     


     


    

 


IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above.


 


	 	OPH F LIMITED
	 	 
	 	By:	/s/ Martin Lau
	 	Name: 	 Lau Chiping Martin
	 	Title:	Authorized Representative
	 	 	 
	 	Address:
	 	 
	 	c/o Tencent Holdings Limited

                                             Level 29, Three Pacific Place

                                             No. 1 Queen's Road East

                                             Wanchai, Hong Kong

	 	Attn:	      Richard Pu
	 	 	 
	 	With a copy to:
	 	 
	 	Tencent Building
	 	Kejizhongyi Avenue, Hi-tech Park

                                             Nanshan District, Shenzhen, 518057

	 	P.R. China
	 	Attn:	     Bill Zhan


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above. 


 


	 	Redpoint Ventures IV,  L.P., by its General Partner
	 	Redpoint Ventures IV, LLC
	 	 
	 	Redpoint Ventures IV, LLC, as nominee
	 	 
	 	By: 	/s/ Scott C. Raney
	 	 	Scott C. Raney, Managing Director
	 	 
	 	Address:
	 	 
	 	3000 Sand Hill Road
	 	Building 2, Suite 290
	 	Menlo Park, CA 94025


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	Aviv Nevo
	 	 
	 	/s/ Aviv Nevo
	 	 
	 	Address:
	 	 
	 	301 Arizona Avenue
	 	Suite 310
	 	Santa Monica, CA 90401


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.


 


	 	JOHN HERING, TRUSTEE
	 	THE JOHN HERING LIVING TRUST
	 	 
	 	By: 	/s/ John Hering
	 	 	Trustee
	 	 
	 	Address:
	 	401 Harrison St #3903
	 	San Francisco, CA 94105


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	ROSEHEARTY INVESTMENTS LLC
	 	 
	 	By:	 /s/ Clare Sweeney
	 	Name:	 Clare Sweeney
	 	Title: 	Secretary


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	INDEX VENTURES VII (JERSEY), L.P
	 	 
	 	By: its Managing General Partner:
	 	Index Venture Associates VII Limited
	 	 
	 	/s/ Nigel Greenwood
	 	Nigel Greenwood
	 	Director
	 	 
	 	Address:
	 	Index Venture Associates VII Limited
	 	No 1 Seaton Place
	 	St Helier
	 	Jersey JE4 8YJ
	 	Channel Islands
	 	Attention: Danielle Cox
	 	Tel +44 (0) 1534 605749
	 	Fax +44 (0) 1534 605605
	 	 
	 	INDEX VENTURES VII PARALLEL
	 	ENTREPRENEUR FUND (JERSEY), L.P.
	 	 
	 	By: its Managing General Partner:
	 	Index Venture Associates VII Limited
	 	 
	 	/s/ Nigel Greenwood
	 	Nigel Greenwood
	 	Director
	 	 
	 	Address:
	 	Index Venture Associates VII Limited
	 	No 1 Seaton Place
	 	St Helier
	 	Jersey JE4 8YJ
	 	Channel Islands
	 	Attention: Danielle Cox
	 	Tel +44 (0) 1534 605749
	 	Fax +44 (0) 1534 605605


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	YUCCA (JERSEY) SLP
	 	 
	 	By: Elian Employee Services Limited as
	 	Authorised Signatory of Yucca (Jersey) SLP in
	 	its capacity as administrator of the Index Co-
	 	Investment Scheme
	 	 
	 	/s/ Elian Employment Benefit Services Limited
	 	Authorised Signatory – Elian Employment Benefit
	 	Services Limited
	 	 
	 	Address:
	 	 
	 	44 Esplanade
	 	St Helier
	 	Jersey JE4 9WG
	 	Channel Islands
	 	Facsimile +44 (0) 1534 504444
	 	Attention: Sarah Earles
	 	 
	 	With copies to:
	 	Index Venture Management S.A.
	 	2 rue de Jargonnant
	 	1207 Geneva
	 	Switzerland
	 	Fax +41 22 737 0099
	 	Attention: Andre Dubois


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	TWITTER, INC.
	 	 
	 	By:	 /s/ Richard Costolo
	 	Name:	 Richard Costolo
	 	Title:	Chief Executive Officer


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	Telefonica Open Future, S.L.U.
	 	 
	 	/s/ Ana Segurado Escudero
	 	By:	Ana Segurado Escudero
	 	Title:	 Director
	 	 
	 	/s/ Diego Colchero Paetz
	 	By:	Diego Colchero Paetz
	 	Title:	 Director


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	QUALCOMM Incorporated
	 	 
	 	By:	/s/ Adam Schwenker
	 	Name: 	 Adam Schwenker
	 	Title:	Vice-President and Legal Counsel


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	SALESFORCE.COM, INC.
	 	 
	 	By:	/s/ John Somorjai                     
	 	Name: 	 John Somorjai
	 	EVP, Corporate Development and
	 	Salesforce Ventures


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	AI Value Holdings, LLC
	 	 
	 	By Access Industries Management, LLC, its manager
	 	 
	 	By:	/s/ Peter L. Thoren
	 	Name: 	 Peter L. Thoren
	 	Title:	Executive Vice President
	 	 
	 	 
	 	By:	/s/ Richard B. Storey
	 	Name:	 Richard B. Storey
	 	Title:	Executive Vice President


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	BRYON EQUITIES CAPITAL LTD.
	 	 
	 	By:	 /s/ Lo, Tsung Kuei
	 	Name: 	 Lo, Tsung Kuei
	 	Title:	Director


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	SANTANDER FINTECH LIMITED
	 	 
	 	By:	/s/ Richard Brown
	 	Name: 	 Richard Brown
	 	Title:	Investment Director
	 	For and on behalf of Santander Fintech Limited


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	PAUL SHUSTAK
	 	 
	 	By:	 /s/ Paul Shustak


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	(If an Entity)
	 	 
	 	/s/ Nautilus Venture Partners, Fund I
	 	Entity
	 	 
	 	By:	 /s/ Connie Sheng
	 	Name: 	 Connie Sheng
	 	Title:	Managing Director
	 	 
	 	Address:
	 	 
	 	14904 Sobey Rd
	 	Saratoga, CA 95070


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	(If an Entity)
	 	 
	 	/s/ Rosy Ace Limited
	 	Entity
	 	 
	 	By:	 /s/ Peter Pan
	 	Name:	 Peter Pan
	 	Title:	Director
	 	 
	 	Address:
	 	 
	 	No. 4, Mingsheng Street
	 	Tucheng Dist., New Taipei City
	 	23679, Taiwan


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.


 


	 	(If an Entity)
	 	 
	 	FOXTEQ HOLDINGS INC.
	 	Entity
	 	 
	 	By:	 /s/ Yu Huang, Chiu-Lian
	 	Name:	 Yu Huang, Chiu-Lian
	 	Title:	Director
	 	 
	 	Address:
	 	 
	 	No. 2, Ziyou Street, Tucheng District
	 	New Taipei City, 23678
	 	Taiwan


 


SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.


 




     


     


    

 


SCHEDULE
A


 


SERIES A INVESTORS


 


	Name and Address	 	Shares of Series A Preferred Stock
    Held
	 	 	 
	
    Benchmark Capital Partners VII, L.P. 2965 Woodside Road

    Woodside, CA 94062
	 	8,038,585
	 	 	 
	Redpoint Ventures IV, L.P. 3000 Sand Hill Road Building 2,

Suite 290 Menlo Park, CA 94025	 	1,710,826
	 	 	 
	
    Redpoint Associates IV, LLC 3000 Sand Hill Road
Building 2,

Suite 290 Menlo Park, CA 94025
	 	43,847
	 	 	 
	
    TWB Investment Partnership II, L.P. 1201 Third Street, Floor
    49

    Seattle, WA 98101
	 	73,078
	 	 	 
	
    Terry K. Quan, P.C. 1239 Fernside Drive

    La Cañada Flintridge, CA 91011
	 	14,615
	 	 	 
	
    White Malula LLC 2131 22nd Street

    Santa Monica, CA 90405
	 	14,615
	 	 	 
	
    Jean-Paul Colaco Trust 223 13th Place

    Manhattan Beach, CA 90266
	 	73,078
	 	 	 
	
    Felix Anthony

    233 14th Avenue E, Apt. 107

    Seattle, WA 98112
	 	58,462
	 	 	 
	
    Michael Lee

    480 Cowper Street, Suite 280 Palo Alto, CA 94301
	 	58,462
	 	 	 
	
    William Flora

    615 17th Avenue E Seattle, WA 98112
	 	14,615



 



     


     


    

 


	Name
                                            and Address
	 	Shares
                                            of Series A Preferred Stock Held

	 	 	 
	
    Daniel Pepper

    2530 56th Avenue SW Seattle, WA 98116
	 	14,615
	 	 	 
	
    Eric Braff

    2530 56th Avenue SW Seattle, WA 98116
	 	14,615
	 	 	 
	
    Mark Gibson

    1826 E. Howell Street Seattle, WA 98122
	 	14,615
	 	 	 
	
    Robert Lee

    883 46th Avenue

    San Francisco, CA 94121
	 	14,615



 



     


     


    

 


SCHEDULE B 


 


SERIES B INVESTORS 


 


	Name
    and Address	 	Shares
    of Series B Preferred Stock Held
	 	 	 
	Andreessen Horowitz Fund III, L.P. 2865 

    Sand Hill Road, Suite 101	 	4,947,110
	Menlo Park, CA 94025	 	 
	Attn: Shawn Conway	 	 
	Email: shawn@a16z.com	 	 
	 	 	 
	Benchmark Capital Partners VII, L.P. 

    2965 Woodside Road	 	692,418
	Woodside, CA  94062	 	 
	Attn: Mitch Lasky	 	 
	Email: mitch@benchmark.com	 	 
	 	 	 
	Redpoint Ventures IV, L.P. 

    3000 Sand Hill Road	 	560,196
	Building 2, Suite 290	 	 
	Menlo Park, CA 94025	 	 
	Attn: Scott Raney	 	 
	Email: sraney@redpoint.com	 	 
	 	 	 
	Redpoint Associates IV, LLC 

    3000 Sand Hill Road	 	14,364
	Building 2, Suite 290	 	 
	Menlo Park, CA 94025	 	 
	Attn: Scott Raney	 	 
	Email: sraney@redpoint.com	 	 



 



     


     


    

 


	Name and
    Address	 	Shares
    of Series B Preferred Stock Held
	 	 	 
	OPH
    F Limited, a BVI Company	 	324,110
	c/o
    Tencent Holdings Limited	 	 
	Level
    29, Three Pacific Place	 	 
	No.
    1 Queen’s Road East	 	 
	Wanchai,
    Hong Kong	 	 
	Attn:
    Richard Pu	 	 
	Email:
    richardpu@tencent.com.hk	 	 
	 	 	 
	With
    a copy to:	 	 
	 	 	 
	Tencent
    Building	 	 
	Kejizhongyi
    Avenue, Hi-tech Park	 	 
	Nanshan
    District, Shenzhen, 518057	 	 
	P.R.
    China	 	 
	Attn:
    Bill Zhan	 	 
	Email:
    bill@tencent.com	 	 
	 	 	 
	TWB
    Investment Partnership II, L.P.	 	11,786
	1201
    Third Street, Floor 49	 	 
	Seattle,
    WA 98101	 	 
	Email:
    barnheim@perkinscoie.com	 	 
	 	 	 
	Terry
    K. Quan, P.C. 1239 Fernside Drive	 	2,210
	 	 	 
	La Cañada Flintridge,
    CA 91011	 	 
	Email: terry@foundationllp.com	 	 
	 	 	 
	Paul
    Shustak	 	2,210
	120 S. Sycamore Avenue	 	 
	Los Angeles, CA 90036	 	 
	Email: paulshu@yahoo.com	 	 
	 	 	 
	Donald
    Whitlatch	 	1,474
	501 Mystic Way	 	 
	Laguna Beach, CA 92651	 	 
	Email: whitco@cox.net	 	 
	 	 	 
	David
    J. Kondik II and Mandy E. Kondik, as	 	1,474
	joint tenants	 	 
	259 Scenery Drive	 	 
	Weirton, WV 26062	 	 
	Email: mandykondik@hotmail.com	 	 



 



     


     


    

 


	Name
and Address
	 	Shares
of Series B Preferred Stock Held

	 	 	 
	David J.
    Kondik and Joann R. Kondik 248 

Scenery Drive

    Weirton,
    WV 26062

    Email:
    jdkondik@hotmail.com
	 	1,474
	 	 	 
	Jose T.
    Suro

    3155 Frontera
    Way, #312

    Burlingame,
    CA 94010 

Email: jt1suro@hotmail.com
	 	1,474
	 	 	 
	Wayne Woods

    6670 Ambrosia
    Lane #522

    Carlsbad,
    CA 92011 wws2000@aol.com
	 	737
	 	 	 
	Eric Wise

    3445 Redwood
    Avenue Los Angeles, CA 

90066 Email: ewise@isbx.com
	 	1,474
	 	 	 
	Paul Wimmers
    949 Lake Street

    Venice,
    CA 90291

    Email:
    paulwimmers@hotmail.com
	 	737
	 	 	 
	Sheldon
    McMaster 74 Moxham Drive 

Sydney, Nova Scotia CANADA B1S 2A1

    Email:
    sheldonmcmaster@hotmail.com
	 	1,474
	 	 	 
	HoangYen
    T Nguyen 3003 Olin Ave Unit 

#117 San Jose CA 95128

    Email:
    yenhoang712@gmail.com
	 	1,474
	 	 	 
	Aileen
    Taylor 187 Somme SW Calgary, 

Alberta Canada T2T 5J8

    Email:
    aileenmarie@shaw.ca
	 	1,474 



 



     


     


    

SCHEDULE C


 


SERIES C INVESTORS


 


	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	PI International
    Holdings LLC 455 N. 

Whisman Road, Suite 100 Mountain View, 

CA 94043

    Attn: Rajesh
    Ramaiah and Shruti 

Chandrasekhar

    Email:
    rajesh@premjiinvest.com;

 shruti@premjiinvest.com
	 	1,582,950
	 	 	 
	Andreessen
    Horowitz Fund III, L.P. 2865 

Sand Hill Road, Suite 101 Menlo Park, CA 

94025

    Attn: Shawn
    Conway 

Email: shawn@a16z.com
	 	287,718
	 	 	 
	Benchmark
    Capital Partners VI, L.P. 

2965 Woodside Road

    Woodside,
    CA 94062 

Attn: Mitch Lasky

    Email:
    mitch@benchmark.com
	 	290,162
	 	 	 
	Benchmark
    Capital Partners VII, L.P. 

2965 Woodside Road

    Woodside,
    CA 94062 

Attn: Mitch Lasky

    Email:
    mitch@benchmark.com
	 	217,622
	 	 	 
	OPH F Limited,
    a BVI Company 

c/o Tencent Holdings Limited 

Level 29, Three Pacific 

Place No. 1 Queen’s Road East Wanchai, Hong Kong

    Attn: Richard
    Pu

    Email:
    richardpu@tencent.com.hk
	 	18,850
	 	 	 
	With
    a copy to:	 	 
	 	 	 
	Tencent
    Building

    Kejizhongyi
    Avenue, Hi-tech Park Nanshan District, Shenzhen, 518057

    P.R. China
    Attn: Bill Zhan

    Email:
    bill@tencent.com
	 	 



 



     


     


    

 


	Name
and Address
	 	

    Shares
    of Series C Preferred Stock Held

	 	 	 
	Redpoint
    Ventures IV, L.P.

 3000 Sand Hill Road Building 2, 

Suite 290 Menlo Park, CA 94025 

Attn: Scott Raney

    Email:
    sraney@redpoint.com
	 	132,033
	 	 	 
	Redpoint
Associates IV, LLC 

3000 Sand Hill Road Building 2, 

Suite 290 Menlo Park, CA 94025 

Attn: Scott Raney

    Email:
    sraney@redpoint.com
	 	3,385
	 	 	 
	Aviv Nevo

    301 Arizona
    Avenue, 

Suite 310 Santa Monica, CA 90401

    Attn: Aviv
    Nevo 

Tel: 310-393-0934

    Email:
    vivi@nvinvestinc.com 

Email: office@nvinvestinc.com
	 	63,318
	 	 	 
	John Hering,
    Trustee of the John Hering Living Trust 401 Harrision Street, #3903

    San Francisco,
    CA 94105 

Attn: John Hering, Trustee

    Email:
    john.hering@lookout.com
	 	6,332
	 	 	 
	Rosehearty
    Investments LLC

    1211 Avenue
    of the Americas, 

8th floor New York, NY 10036

    Attn: Paula
    M. Wardynski 

Email: paulaw@21cf.com
	 	316,590
	 	 	 
	Index Ventures
    VII (Jersey), L.P.

    c/o Index
    Venture Associates VII Limited 

No 1 Seaton Place

    St Helier
    Jersey JE4 8YJ

    Channel
    Islands 

Attn: Danielle Cox

    Tel: +44
    (0) 1534 605749

    Fax + 44
    (0) 1534 605605
	 	152,150



 



     


     


    

 


	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	Index Ventures VII Parallel
    Entrepreneur Fund (Jersey), L.P.	 	3,770
	Index Venture
    Associates VII Limited No 1 Seaton Place

    St Helier
    Jersey JE4 8YJ

    Channel
    Islands Attn: Danielle Cox

    Tel: +44
    (0) 1534 605749

    Fax + 44
    (0) 1534 605605
	 	 
	 	 	 
	YUCCA (JERSEY)
    SLP

    44 Esplanade
    St Helier

    Jersey
    JE4 9WG Channel Islands

    Facsimile
    +44 (0) 1534 504444 

Attn: Hollie Benec'h
	 	2,375
	 	 	 
	With copies to:	 	 
	 	 	 
	Index Venture
    Management S.A. 

2 rue de Jargonnant

    1207 Geneva
    Switzerland

    Fax: +41
    22 737 0099

    Attn: Andre
    Dubois
	 	 
	 	 	 
	Twitter,
    Inc.

    1355 Market
    Street, 

Suite 900 San Francisco, CA 94103

    Attn: Mike
    Gupta,

    Senior Vice President
	 	126,636
	 	 	 
	with copies to:	 	 
	 	 	 
	Attn: General Counsel twitterventures@twitter.com	 	 
	 	 	 
	QUALCOMM
    Incorporated 

5775 Morehouse Drive

    San Diego,
    CA 92121 

Attn: Adam Schwenker

    Email:
    aschwenker@qualcomm.com
	 	316,590



 



     


     


    

 


	Name and Address	 	Shares of Series C Preferred
    Stock Held
	 	 	 
	Salesforce.com,
    Inc.

    The Landmark
    @ One Market St., 

Suite 300 San Francisco, CA 94105

    Attn: John
    Somorjai, EVP Corporate Development

 Email: jsomorjai@salesforce.com
	 	316,590
	 	 	 
	AI Value
    Holdings, LLC c/o 

Access Industries, Inc.

    730 Fifth
    Avenue, 20th Floor New York, NY 10019

    Attn: Jared
    Fertman

    Email:
    jfertman@accind.com
	 	443,226
	 	 	 
	Telefónica
    Open Future, S.L.U. Ronda de la Comunicación s/n Distrito Telefónica, Edificio Oeste 2 28049 Madrid, Spain

    Attn: Ana
    Segurado Escudero

    Email:
    ana.seguradoescudero@telefonica.com

    Attn: Diego Colchero Paetz

    Email:
    dcolchero@telefonica.com
	 	158,295
	 	 	 
	Bryon Equities
    Capital Ltd. Vanterpool Plaza,

 2nd Floor, Wickhams Cay I,

    Road Town,
    Tortola, British Virgin Islands
	 	316,590
	 	 	 
	Notice to be provided to:	 	 
	 	 	 
	Roderick
    Purwana Chairman Office

    Sinarmas
    Land Plaza, Tower 2, Level 33

    Jl. MH.Thamrin
    51, Kav. 22, Jakarta Pusat 10350, Indonesia

    Email:
    roderick.purwana@sinarmas-agri.com
	 	 
	 	 	 
	Santander
    Fintech Limited 2 Triton Square

    London
    NW1 3AN United Kingdom

    Email:
    ants.secretariat@santander.co.uk 

Attn: Company Secretary
	 	158,295
	 	 	 
	Paul Shustak

    120 S.
    Sycamore Avenue Los Angeles, CA 90036

    Email:
    paulshu@yahoo.com
	 	1,583



 



     


     


    

 


	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	Nautilus
    Venture Partners, Fund I 14906 Sobey Road

    Saratoga,
    CA 95070 Attn: Connie Sheng

    Email:
    connie@nautilusvp.com
	 	25,328
	 	 	 
	Rosy Ace
    Limited

    No. 4,
    Minsheng Street, Tucheng District New Taipei City

    23679

    Taiwan

    Attn: Francis
    C.H. Chen

    Email:
    francis.ch.chen@foxconn.com
	 	189,954
	 	 	 
	FOXTEQ
    HOLDINGS INC.

    No. 2,
    Ziyou Street, Tucheng District New Taipei City

    23678

    Taiwan

    Attn: Francis
    C.H. Chen

    Email:
    francis.ch.chen@foxconn.com
	 	126,636



 



     


     


    

 


SCHEDULE D


 


KEY HOLDERS




 


	Kirt McMaster	 	 
	3003 Olin Avenue, 

#117 San Jose, CA 

95128 

Email:
    kirt@cyngn.com	 	 
	 	 	 
	Steven Kondik 

20182 110th P1 

SE Kent, WA 

98031	 	 
	Email: steve@cyngn.com	 	 
	 	 	 
	Koushik Dutta	 	 
	2929 1st Avenue 600	 	 
	Seattle, WA 98121	 	 
	Email: koush@koushikdutta.com	 	 
	 	 	 
	Tom Moss	 	 
	97 Pepper Drive	 	 
	Los Altos, CA 94022	 	 
	Email: droid24601@gmail.com